University of Birmingham - Proximity to Discovery 2017
Lead Research Organisation:
University of Birmingham
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The MRC Proximity to Discovery scheme awards universities funds to help develop new collaborations, and ways of exchanging knowledge and skills. The awards can be used to support activities that promote the value of academic-industry partnership, and enhance academic and industry researchers’ understanding of each other’s needs and capabilities. This may be through people exchanges, creation of technology demonstrators, showcase events, commercialisation workshops and ‘entrepreneurs in residence’ schemes. Such exchanges of knowledge and skills will boost the most fruitful collaborations between UK universities and life science companies.
Organisations
Publications
Braithwaite T
(2019)
Cochrane corner: why we still don't know whether anti-TNF biologic therapies impact uveitic macular oedema.
in Eye (London, England)
Calvert MJ
(2019)
Harnessing the patient voice in real-world evidence: the essential role of patient-reported outcomes.
in Nature reviews. Drug discovery
Cao X
(2022)
Optimisation of single contour strategy in selective laser melting of Ti-6Al-4V lattices
in Rapid Prototyping Journal
Colicchia M
(2022)
S100A8/A9 drives the formation of procoagulant platelets through GPIba
in Blood
Faustini SE
(2020)
Detection of antibodies to the SARS-CoV-2 spike glycoprotein in both serum and saliva enhances detection of infection.
in medRxiv : the preprint server for health sciences
Ginestra P
(2020)
Post Processing of 3D Printed Metal Scaffolds: a Preliminary Study of Antimicrobial Efficiency
in Procedia Manufacturing
Hill LJ
(2018)
Sustained release of decorin to the surface of the eye enables scarless corneal regeneration.
in NPJ Regenerative medicine
Iacucci M
(2021)
An International Multicenter Real-Life Prospective Study of Electronic Chromoendoscopy Score PICaSSO in Ulcerative Colitis.
in Gastroenterology
Li X
(2019)
Derivatisation of parthenolide to address chemoresistant chronic lymphocytic leukaemia.
in MedChemComm
Liu X
(2020)
Instrument-based Tests for Measuring Anterior Chamber Cells in Uveitis: A Systematic Review.
in Ocular immunology and inflammation
McKemey E
(2021)
Resolution of Persistent COVID-19 After Convalescent Plasma in a Patient with B Cell Aplasia.
in Journal of clinical immunology
McMullan C
(2023)
Development and usability testing of an electronic patient-reported outcome (ePRO) solution for patients with inflammatory diseases in an Advanced Therapy Medicinal Product (ATMP) basket trial.
in Journal of patient-reported outcomes
Morley GL
(2020)
Sensitive Detection of SARS-CoV-2-Specific Antibodies in Dried Blood Spot Samples.
in Emerging infectious diseases
Panetti S
(2023)
Engineering amino acid uptake or catabolism promotes CAR T-cell adaption to the tumor environment.
in Blood advances
Perez-Toledo M
(2020)
Serology confirms SARS-CoV-2 infection in PCR-negative children presenting with Paediatric Inflammatory Multi-System Syndrome.
in medRxiv : the preprint server for health sciences
Perez-Toledo M
(2021)
SARS-CoV-2-specific IgG1/IgG3 but not IgM in children with Pediatric Inflammatory Multi-System Syndrome.
in Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology
Serrage HJ
(2019)
Differential responses of myoblasts and myotubes to photobiomodulation are associated with mitochondrial number.
in Journal of biophotonics
Shields A
(2020)
SARS-CoV-2 seroprevalence and asymptomatic viral carriage in healthcare workers: a cross-sectional study.
in Thorax
Shields AM
(2021)
Serological responses to SARS-CoV-2 following non-hospitalised infection: clinical and ethnodemographic features associated with the magnitude of the antibody response.
in BMJ open respiratory research
Shields AM
(2020)
Serological responses to SARS-CoV-2 following non-hospitalised infection: clinical and ethnodemographic features associated with the magnitude of the antibody response.
in medRxiv : the preprint server for health sciences
Watson J
(2020)
Testing for SARS-CoV-2 antibodies.
in BMJ (Clinical research ed.)
Description | Barts Charity |
Amount | £87,040 (GBP) |
Organisation | Barts Charity |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 11/2020 |
End | 10/2025 |
Description | Birmingham CRUK Centre local support |
Amount | £18,050 (GBP) |
Funding ID | C17422/A25154 |
Organisation | Cancer Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 05/2018 |
End | 12/2018 |
Description | CRUK Cancer Immunology Project Award |
Amount | £286,421 (GBP) |
Funding ID | C54019/A27535 |
Organisation | Cancer Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 02/2019 |
End | 01/2022 |
Description | Department of Health and Social Care / University of Oxford |
Amount | £269,735 (GBP) |
Organisation | Department of Health (DH) |
Sector | Public |
Country | United Kingdom |
Start | 11/2020 |
End | 10/2021 |
Description | Development of Anti-viral Air Filters to Protect Passengers on Trains |
Amount | £17,908 (GBP) |
Organisation | Royal Academy of Engineering |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 07/2020 |
End | 06/2021 |
Description | Dissecting the dynamic changes in the innate immune cells of tumours to enhance immune checkpoint blockade therapies |
Amount | £20,000 (GBP) |
Organisation | AstraZeneca |
Department | MedImmune |
Sector | Private |
Country | United Kingdom |
Start | 10/2018 |
End | 09/2022 |
Description | Industry funding |
Amount | £207,500 (GBP) |
Organisation | Principia Biopharma |
Sector | Private |
Country | United States |
Start | 04/2020 |
End | 11/2021 |
Description | LifeArc |
Amount | £420,746 (GBP) |
Organisation | LifeArc |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 08/2019 |
End | 12/2022 |
Description | Measurement of extracellular vesicles in cardiovascular disease by a novel interferometric imaging method- (Mr Joshua Price) |
Amount | £107,927 (GBP) |
Funding ID | FS/19/68/34583 |
Organisation | British Heart Foundation (BHF) |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 01/2020 |
End | 12/2022 |
Description | Ministry of Defence |
Amount | £134,000 (GBP) |
Organisation | Ministry of Defence (MOD) |
Sector | Public |
Country | United Kingdom |
Start | 12/2020 |
End | 11/2021 |
Description | Patient-reported outcomes assessment to support accelerated access to advanced cell and gene therapies: PROmics |
Amount | £1,185,446 (GBP) |
Funding ID | 104777 |
Organisation | Innovate UK |
Sector | Public |
Country | United Kingdom |
Start | 12/2018 |
End | 03/2021 |
Description | Rapid Design of Bioinspired Alloys - From Modelling to Manufacture |
Amount | £1,185,027 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 11/2021 |
End | 10/2025 |
Description | Research Development Fund |
Amount | £4,500 (GBP) |
Funding ID | Harrison |
Organisation | University of Birmingham |
Sector | Academic/University |
Country | United Kingdom |
Start |
Description | Revealing antitumor T cell recruitment and recirculation in vivo to optimise therapeutic intervention |
Amount | £286,421 (GBP) |
Organisation | Cancer Research UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 02/2019 |
End | 01/2022 |
Description | Topical delivery of Mitia drug using Cell Penetrating Peptide |
Amount | £509,997 (GBP) |
Organisation | Macregen |
Sector | Private |
Country | United States |
Start | 03/2018 |
End | 09/2019 |
Description | UKRI COVID-19 Rapid Response Rolling Call |
Amount | £708,036 (GBP) |
Funding ID | MR/W002663/1 |
Organisation | United Kingdom Research and Innovation |
Sector | Public |
Country | United Kingdom |
Start | 02/2021 |
End | 07/2022 |
Description | Wellcome ISSF |
Amount | £170,486 (GBP) |
Funding ID | ISSF3 HC3 |
Organisation | Wellcome Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 10/2018 |
End | 09/2022 |
Description | Wellcome ISSF Continuity Award |
Amount | £28,373 (GBP) |
Organisation | Wellcome Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 01/2020 |
End | 12/2020 |
Description | Wellcome Translational Development Fund (UoB internal) |
Amount | £33,592 (GBP) |
Funding ID | TDF 1.1 |
Organisation | Wellcome Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 01/2020 |
End | 03/2021 |
Description | Wellcome Translational Development Fund (UoB internal) |
Amount | £18,332 (GBP) |
Funding ID | TDF 1.2 |
Organisation | Wellcome Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 11/2020 |
End | 06/2021 |
Description | Worldwide Cancer Research |
Amount | £170,685 (GBP) |
Organisation | Worldwide Cancer Research |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 05/2021 |
End | 04/2023 |
Description | Presentation at World Biomaterial's Conference (WBC2020) |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Professional Practitioners |
Results and Impact | Presentation at World Biomaterial's Conference (WBC2020): Louth, S. Villapun, V.M., Eisenstein, N., Attalah, M., Nai, K. & Cox, S. Using Additively Manufactured Lattices to Control Antibiotic Release in a Temporary Hip Spacer. Impacts not known. |
Year(s) Of Engagement Activity | 2020 |